Eli Lilly and Co’s experimental pill for rheumatoid arthritis proved superior to Abbvie Inc’s leading injectable Humira treatment in a large study, which analysts said could prod them to raise sales forecasts for the medicine. Lilly said on Wednesday it was the first study to show that a once-daily oral treatment was superior to $13 […]
Japan’s Astellas is seeking more deals to refill its drug pipeline as the pharmaceutical company created through a merger 10 years ago explores opportunities in both established and new therapy areas. “We’re never satisfied with what we have, so we are looking at strategies to augment the portfolio. Nothing is off the table for […]
(Reuters Health) – The proportion of people reporting use of prescription opioids for reasons other than medical necessity fell between 2003 and 2013, but use disorders and overdose deaths increased, according to a new study. “The results underscore the importance of addressing the prescription opioid crisis,” said lead author Dr. Beth Han of the Substance Abuse […]
Karmiel, Israel-based Protalix Biotherapeutics, Inc. (PLX) announced today that it was selling its share of a collaboration deal back to Pfizer Inc. (PFE) Under the original deal, Pfizer took 60 percent and Protalix took 40 percent of revenues and expenses for the development and commercialization of ELELYSO, except in Israel and Brazil. Under the […]
The odds that Merck & Co’s high-stakes cholesterol drug will succeed have dropped dramatically after Eli Lilly and Co said its similar medicine failed to reduce heart attacks and strokes, top U.S. heart doctors said. Lilly on Monday said it was halting a 12,000-patient study of its drug, evacetrapib, an oral medication. In earlier studies, […]
CANTON, Mass. – Collegium Pharmaceutical, Inc. ’s (COLL) stock is down nearly 10 percent in aftermarket trading after the company announced the U.S. Food and Drug Administration will not complete a review of the company’s extended-release opioid pain medication drug Xtampza. Michael Heffernan, Collegium’s chairman and chief executive officer, said the company remains confident […]
With not one but two record-shattering product launches that transformed the treatment of hepatitis C, Gilead more than doubled its revenue in a single year, earning its place as Med Ad News’ Company of the Year.
Med Ad News spoke with Paul Carter, Gilead’s executive VP of commercial operations, regarding the success of Sovaldi and Harvoni as well as the company’s vision of the future of biopharmaceuticals.
Amgen has been an independent biotech leader for years with an established array of blockbuster products, and now the company’s next wave of promising medicines is making its mark.